Participants received nivo+rela or nivo+ipi for clinically palpable stage III resectable melanoma as part of a therapeutic clinical trial

Participants had history of diagnosis of any malignancy (except for non-melanoma skin cancer) in the last 2 years.

Participants received adjuvant nivo+rela or adjuvant nivo+ipi after neoadjuvant nivo+ipi

Participants received adjuvant nivo+ipi after neoadjuvant nivo+rela

Participants received any systemic therapy prior to the initiation of neoadjuvant nivo+rela or nivo+ipi

Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab